Table 1 Clinical features of patients with GBS

Sex

Male

90

69.23

Female

40

30.77

Age

< 60 y

107

82.31

≥ 60 y

23

17.69

Season of disease onset

Spring or summer

81

62.31

Autumn or winter

49

37.69

History of chronic diseases

Hypertension

19

14.62

Diabetes

9

6.92

Precursor event

Yes

78

60

Duration of disease before admission

< 2 weeks

96

73.85

≥ 2 weeks

34

26.15

Clinical symptoms

Isolated limb weakness

27

20.77

Pure limb paresthesia

8

6.15

Limb weakness with associated limb paresthesia

38

29.23

Combined with cranial nerve damage

57

43.85

Limb tendon reflexes

Weaken/fade away

119

91.50

Normal

9

6.92

Tendon hyperreflexia

2

1.54

Autonomic nerve involvement

Yes

20

15.38

No

110

84.62

Pneumonia

Yes

17

13.08

No

113

86.92

Duration of disease before lumbar puncture

≤ 2 weeks

82

63.08

> 2 weeks

48

36.92

CSF white blood cell count (*10^6/L)

< 5

96

73.85

5–10

21

16.15

11–30

11

8.46

> 30

2

1.54

CSF Protein level (mg/dL)

≥ 45

111

85.38

< 45

19

14.62

Ganglioside antibody detection

Positive

22

16.92

Negative

21

16.15

Unknown

87

66.92

Electrophysiological classification

AIDP

106

81.54

MFS

21

16.15

AMAN

2

4.54

AMSAN

1

0.77

Disease severity

Mild

95

73.08

Severe

35

26.92

Medication administered

IVIG

55

42.31

Glucocorticoid

23

17.69

IVIG + Glucocorticoid

47

36.15

PE

2

1.54

None

3

2.31

Long-term prognosis

Favorable

120

92.31

Poor prognosis

10

7.69